Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Huazhong Univ. of Science and Technology AHR compound B19: sourced facts only. name: "Among them, B19 showed low cytotoxicity (>40 μM) and potent AHR agonist activity with an EC50 value of 2.01 nM, which was 14-fold stronger than that of Tapinarof (28.93 nM)." [PMID:40924124]; target: "Among them, B19 showed low cytotoxicity (>40 μM) and potent AHR agonist activity with an EC50 value of 2.01 nM, which was 14-fold stronger than that of Tapinarof (28.93 nM)." [PMID:40924124]; developer: "Hubei Key Laboratory of Natural Medicinal Chemistry and Resource Evaluation, School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China." [PMID:40924124]; stage: "Upon topical application, B19 significantly ameliorated imiquimod (IMQ)-induced psoriasis-like cutaneous manifestations and repaired the barrier function of skin, concurrently downregulating the expression levels of CD206, CD36, IL-18, and MCP-1." [PMID:40924124]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Huazhong Univ. of Science and Technology AHR compound B19.